Browse
Submit Data
Databases
API
Help

Dataset Information

25 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Androgen receptor and MYC equilibration centralizes on developmental super-enhancer.

ABSTRACT: Androgen receptor (AR) in prostate cancer (PCa) can drive transcriptional repression of multiple genes including MYC, and supraphysiological androgen is effective in some patients. Here, we show that this repression is independent of AR chromatin binding and driven by coactivator redistribution, and through chromatin conformation capture methods show disruption of the interaction between the MYC super-enhancer within the PCAT1 gene and the MYC promoter. Conversely, androgen deprivation in vitro and in vivo increases MYC expression. In parallel, global AR activity is suppressed by MYC overexpression, consistent with coactivator redistribution. These suppressive effects of AR and MYC are mitigated at shared AR/MYC binding sites, which also have markedly higher levels of H3K27 acetylation, indicating enrichment for functional enhancers. These findings demonstrate an intricate balance between AR and MYC, and indicate that increased MYC in response to androgen deprivation contributes to castration-resistant PCa, while decreased MYC may contribute to responses to supraphysiological androgen therapy.

SUBMITTER: Guo H

PROVIDER: S-EPMC8674345 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-10-29 | GSE157107 | GEO

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry (HiChIP)

Project description:We used RNA-Seq, ChIP-Seq, 4C-Seq and HiChIP to assess the role of MYC in the transcriptional repression induced by DHT in prostate cancer.

2021-10-29 | GSE157974 | GEO

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry (4C-Seq)

Project description:We used RNA-Seq, ChIP-Seq and 4C-Seq to assess the role of MYC in the transcriptional repression induced by DHT in prostate cancer.

2021-10-29 | GSE157106 | GEO

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry (ChIP-Seq)

Project description:We used RNA-Seq, ChIP-Seq and 4C-Seq to assess the role of MYC in the transcriptional repression induced by DHT in prostate cancer.

2021-10-29 | GSE157105 | GEO

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry (RNA-Seq)

Project description:We used RNA-Seq, ChIP-Seq and 4C-Seq to assess the role of MYC in the transcriptional repression induced by DHT in prostate cancer.

2021-10-29 | GSE157104 | GEO

Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation.

Project description:Prostate cancer (PCa) is one of the most frequent tumor types in the male Western population. Early-stage PCa and late-stage PCa are dependent on androgen signaling, and inhibitors of the androgen receptor (AR) axis represent the standard therapy. Here, we studied in detail the global impact of darolutamide, a newly approved AR antagonist, on the transcriptome and AR-bound cistrome in two PCa cell models. Darolutamide strongly depleted the AR from gene regulatory regions and abolished AR-driven transcriptional signaling. Enhancer activation was blocked at the chromatin level as evaluated by H3K27 acetylation (H3K27ac), H3K4 monomethylation (H3K4me1), and FOXA1, MED1, and BRD4 binding. We identified genomic regions with high affinities for the AR in androgen-stimulated, but also in androgen-depleted conditions. A similar AR affinity pattern was observed in healthy and PCa tissue samples. High FOXA1, BRD4, H3K27ac, and H3K4me1 levels were found to mark regions showing AR binding in the hormone-depleted setting. Conversely, low FOXA1, BRD4, and H3K27ac levels were observed at regulatory sites that responded strongly to androgen stimulation, and AR interactions at these sites were blocked by darolutamide. Beside marked loss of AR occupancy, FOXA1 recruitment to chromatin was also clearly reduced after darolutamide treatment. We furthermore identified numerous androgen-regulated super-enhancers (SEs) that were associated with hallmark androgen and cell proliferation-associated gene sets. Importantly, these SEs are also active in PCa tissues and sensitive to darolutamide treatment in our models. Our findings demonstrate that darolutamide is a potent AR antagonist blocking genome-wide AR enhancer and SE activation, and downstream transcription. We also show the existence of a dynamic AR cistrome that depends on the androgen levels and on high AR affinity regions present in PCa cell lines and also in tissue samples.

| S-EPMC7463324 | biostudies-literature

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry

Project description:The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry

| PRJNA660117 | ENA

The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry (HiChIP)

Project description:The transcriptional equilibration between androgen receptor and MYC signatures during prostate cancer transition centralizes on a distal developmental super-enhancer circuitry (HiChIP)

| PRJNA663567 | ENA

Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma.

Project description:Osteosarcoma is the most common primary bone sarcoma that mostly occurs in young adults. The causes of osteosarcoma are heterogeneous and still not fully understood. Identification of novel, important oncogenic factors in osteosarcoma and development of better, effective therapeutic approaches are in urgent need for better treatment of osteosarcoma patients. In this study, we uncovered that the oncogene MYC is significantly upregulated in metastastic osteosarcoma samples. In addition, high MYC expression is associated with poor survival of osteosarcoma patients. Analysis of MYC targets in osteosarcoma revealed that most of the osteosarcoma super enhancer genes are bound by MYC. Treatment of osteosarcoma cells with super enhancer inhibitors THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.

| S-EPMC5884797 | biostudies-literature

The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.

Project description:Chromosomal rearrangements are a frequent cause of oncogene deregulation in human malignancies. Overexpression of EVI1 is found in a subgroup of acute myeloid leukemia (AML) with 3q26 chromosomal rearrangements, which is often therapy resistant. In AMLs harboring a t(3;8)(q26;q24), we observed the translocation of a MYC super-enhancer (MYC SE) to the EVI1 locus. We generated an in vitro model mimicking a patient-based t(3;8)(q26;q24) using CRISPR-Cas9 technology and demonstrated hyperactivation of EVI1 by the hijacked MYC SE. This MYC SE contains multiple enhancer modules, of which only one recruits transcription factors active in early hematopoiesis. This enhancer module is critical for EVI1 overexpression as well as enhancer-promoter interaction. Multiple CTCF binding regions in the MYC SE facilitate this enhancer-promoter interaction, which also involves a CTCF binding site upstream of the EVI1 promoter. We hypothesize that this CTCF site acts as an enhancer-docking site in t(3;8) AML. Genomic analyses of other 3q26-rearranged AML patient cells point to a common mechanism by which EVI1 uses this docking site to hijack enhancers active in early hematopoiesis.

| S-EPMC8479123 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data